Horizon presents data showing effectiveness of RAYOS

November 12, 2012

Horizon Pharma announced an additional analysis of data from the pivotal Circadian Administration of Prednisone in Rheumatoid Arthritis-2, CAPRA-2, clinical trial demonstrating that patients with active rheumatoid arthritis (RA) treated with its recently approved RAYOS 5 mg (prednisone) delayed-release tablets had a significant improvement in reduction of fatigue, as determined by the Functional Assessment of Chronic Illness Therapy - Fatigue, FACIT-F, questionnaire. Data were presented during the American College of Rheumatology, ACR/Association of Rheumatology Health Professionals,ARHP, Annual Scientific Meeting in Washington, D.